Tumor budding is an independent adverse prognostic factor in pancreatic ductal adenocarcinoma

American Journal of Surgical Pathology

Volumn 39, Issue 4, 2015, Pages 472-478

  O'Connor, Kate ^a,b   Li Chang, Hector H ^a,b   Kalloger, Steven E ^b,c   Peixoto, Renata D ^b,d   Webber, Douglas L ^a,b,c   Owen, David A ^a,b,c   Driman, David K ^e   Kirsch, Richard ^f   Serra, Stefano ^f   Scudamore, Charles H ^a,c   Renouf, Daniel J ^b,c,d   Schaeffer, David F ^a,b,c  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c Pancreas Centre BC   (Canada)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

^e UNIVERSITY OF WESTERN ONTARIO   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

Author keywords

epithelial mesenchymal transition; pancreatic cancer; pancreatic ductal adenocarcinoma; prognosis; tumor budding

Indexed keywords

TUMOR MARKER;

ADULT; AGED; BIOPSY; CHEMISTRY; CHI SQUARE DISTRIBUTION; DISEASE FREE SURVIVAL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; OBSERVER VARIATION; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; PROPORTIONAL HAZARDS MODEL; REPRODUCIBILITY; RETROSPECTIVE STUDY; RISK FACTOR; STAINING; TIME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; CARCINOMA, PANCREATIC DUCTAL; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OBSERVER VARIATION; PANCREATIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; RISK FACTORS; STAINING AND LABELING; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84925953106     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0000000000000333     Document Type: Article

References (25)

1. Ma J, Siegel R, Jemal A. Pancreatic cancer death rates by race among US men and women, 1970-2009. J Natl Cancer Inst. 2013;105:1694-1700
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11-30
3. Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000;4:567-579
4. Karamitopoulou E. Tumor budding cells, cancer stem cells and epithelial-mesenchymal transition-type cells in pancreatic cancer. Front Oncol. 2013;4:209
5. Sarkar FH, Li Y, Wang Z, et al. Pancreatic cancer stem cells and EMT in drug resistance and metastasis. Minerva Chir. 2009;64: 489-500
6. Wang Z, Li Y, Ahmad A, et al. Pancreatic cancer: understanding and overcoming chemoresistance. Nat Rev Gastroenterol Hepatol. 2011;8:27-33
7. Ueno H, Murphy J, Jass JR, et al. Tumour 'budding' as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology. 2002;40:127-132
8. Ohike N, Coban I, Kim GE, et al. Tumor budding as a strong prognostic indicator in invasive ampullary adenocarcinomas. Am J Surg Pathol. 2010;34:1417-1424
9. Prall F. Tumour budding in colorectal carcinoma. Histopathology. 2007;50:151-162
10. Koike M, Kodera Y, Itoh Y, et al. Multivariate analysis of the pathologic features of esophageal squamous cell cancer: tumor budding is a significant independent prognostic factor. Ann Surg Oncol. 2008;15:1977-1982
11. Gabbert HE, Meier S, Gerharz CD, et al. Tumor-cell dissociation at the invasion front: a new prognostic parameter in gastric cancer patients. Int J Cancer. 1992;50:202-207
12. Zlobec I, Lugli A. Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget. Oncotarget. 2010;1:651-661
13. Lugli A, Vlajnic T, Giger O, et al. Intratumoral budding as a potential parameter of tumor progression in mismatch repairproficient and mismatch repair-deficient colorectal cancer patients. Hum Pathol. 2011;42:1833-1840
14. Mitrovic B, Schaeffer DF, Riddell RH, et al. Tumor budding in colorectal carcinoma: time to take notice. Mod Pathol. 2012;25: 1315-1325
15. Masugi Y, Yamazaki K, Hibi T, et al. Solitary cell infiltration is a novel indicator of poor prognosis and epithelial-mesenchymal transition in pancreatic cancer. Hum Pathol. 2010;41:1061-1068
16. Karamitopoulou E, Zlobec I, Born D, et al. Tumour budding is a strong and independent prognostic factor in pancreatic cancer. Eur J Cancer. 2013;49:1032-1039
17. Li Y, VandenBoom TG, Kong D, et al. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-tomesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res. 2009;69:6704-6712
18. Rotondi MA, Donner A. A confidence interval approach to sample size estimation for interobserver agreement studies with multiple raters and outcomes. J Clin Epidemiol. 2012;65:778-784
19. Horcic M, Koelzer VH, Karamitopoulou E, et al. Tumor budding score based on 10 high-power fields is a promising basis for a standardized prognostic scoring system in stage II colorectal cancer. Hum Pathol. 2013;44:697-705
20. Liang F, Cao W, Wang Y, et al. The prognostic value of tumor budding in invasive breast cancer. Pathol Res Pract. 2013;209: 269-275
21. Wang LM, Kevans D, Mulcahy H, et al. Tumor budding is a strong and reproducible prognostic marker in T3N0 colorectal cancer. Am J Surg Pathol. 2009;33:134-141
22. Harris EI, Lewin DN, Wang HL, et al. Lymphovascular invasion in colorectal cancer: an interobserver variability study. Am J Surg Pathol. 2008;32:1816-1821
23. Kim S, Park HK, Jung HY, et al. ERG immunohistochemistry as an endothelial marker for assessing lymphovascular invasion. Korean J Pathol. 2013;47:355-364
24. Noviello MB, Silva-Filho AL, Traiman P, et al. Inter- and intraobserver variability in the assessment of tumor grade and lymphovascular space invasion in patients with squamous cell carcinoma of the cervix. Eur J Obstet Gynecol Reprod Biol. 2008;138: 246-248
25. Orbo A, Stalsberg H, Kunde D. Topographic criteria in the diagnosis of tumor emboli in intramammary lymphatics. Cancer. 1990;66:972-977